Halozyme Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference Transcript
So our next company here is Halozyme Therapeutics, and with me is Laurie Stelzer. My name is Ashwani Verma. I work with the U.S. major and specialty pharma team at Bank of America. And Laurie, the stage is yours. Let's look at the slides.
Terrific. Thank you, Ash. So good morning, everyone. I'm here today to talk about Halozyme and how we're building a premier biotechnology company, and we're doing this through 2 engines of growth. It's a very unique strategy, very different than many biotech companies, and I'll walk you through that strategy over the next 15 minutes. Naturally, I'll be making some forward-looking statements. So I'll point you to our website for a full list of our risks and uncertainties.
So as I mentioned, we have 2 engines for growth, we have our ENHANZE technology platform, and we have PEGPH20 oncology program. So on our ENHANZE technology platform, this is where -- it's based on a technology
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
